Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Icosapent**, also called eicosapentaenoic acid or EPA, is a long-chain omega-3 polyunsaturated fatty acid used in this Charité-sponsored study as the principal active nutritional component of an EPA-rich, protein- and energy-dense oral nutritional supplement. The completed randomized pilot trial evaluated whether two months of supplementation could improve functional status and quality of life in malnourished patients with colorectal cancer, hepatocellular carcinoma, or cholangiocarcinoma. EPA was investigated as a potentially anticatabolic nutritional substrate in cancer-associated malnutrition. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00168987))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on icosapent.